Lantheus Reports Strong 2025 Financials, Shifts Focus to Radiodiagnostics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy LNTH?
Source: Newsfilter
- Strong Financial Performance: Lantheus reported worldwide revenue of $406.8 million for Q4 2025, a 4.0% increase year-over-year, demonstrating the company's sustained market leadership, particularly in the PYLARIFY product line.
- Significant Profitability Improvement: GAAP earnings per share surged from a loss of $0.17 in the prior year to $0.82, reflecting a remarkable 578.8% increase, showcasing the company's success in cost control and operational efficiency.
- Strategic Focus Shift: The company announced a strategic pivot towards innovative radiodiagnostics, planning to drive long-term growth through acquisitions and the development of new products, especially in the PET radiodiagnostics sector.
- Optimistic Future Outlook: Lantheus projects 2026 revenue between $1.4 billion and $1.45 billion, with adjusted EPS guidance of $5.00 to $5.25, indicating strong confidence in future market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNTH
Wall Street analysts forecast LNTH stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 80.010
Low
70.00
Averages
82.17
High
105.00
Current: 80.010
Low
70.00
Averages
82.17
High
105.00
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantheus Holdings Exceeds 2025 Financial Expectations
- Strong Financial Performance: Lantheus Holdings reported nearly $407 million in revenue for Q4 2025, a 4% increase year-over-year, and despite a slight drop in net income to $111 million, it surpassed the analyst consensus estimate of $1.17 per share, indicating robust market performance.
- Strategic Focus Shift: The company announced a strategic pivot towards innovative radiodiagnostics, prioritizing investments in PET radiodiagnostics while seeking value-maximizing alternatives for its radiotherapeutic assets, reflecting a keen insight into future market demands.
- Sales Dynamics: Although sales of its cancer imaging agent Pylarify fell nearly 10% year-over-year to over $240 million in Q4, the precision diagnostics product category surged 22%, generating over $143 million in revenue, showcasing the company's potential in emerging markets.
- Optimistic 2026 Outlook: Lantheus anticipates revenue between $1.4 billion and $1.45 billion for 2026, with adjusted per-share net profit expected to be between $5 and $5.25, both exceeding current analyst estimates, indicating strong confidence and growth potential for the company.
See More
U.S. Stock Futures Lower, Investors Eye Individual Stocks
- Market Dynamics: U.S. stock futures opened lower this morning on Monday, reflecting a cautious investor sentiment that may influence trading strategies for the day.
- Investor Focus: Despite the overall market decline, certain individual stocks may still attract investor attention, indicating a trend of market differentiation that could lead to capital flowing into specific sectors or companies.
- Expected Volatility: Market participants anticipate greater volatility in the stock market as economic data releases and corporate earnings reports approach, which could impact investor decision-making.
- Data Source: This market analysis is provided by Benzinga, highlighting the importance of real-time tracking and analysis of market dynamics to assist investors in making more informed investment choices.
See More
Lantheus Receives FDA Approval for New Imaging Agent
- FDA Approval: Lantheus Holdings Inc. announced that its new F 18 prostate-specific membrane antigen imaging agent, PYLARIFY TruVu, has received approval from the U.S. Food and Drug Administration (FDA), marking a significant advancement in prostate cancer imaging.
- Defined Indication: PYLARIFY TruVu is indicated for positron emission tomography (PET) imaging in prostate cancer patients, particularly for those with suspected metastasis, which is expected to provide more accurate diagnostic tools for patients.
- Market Launch Plan: The product is expected to be commercially available in the fourth quarter of 2026 and will be introduced on a rolling geographic basis, allowing customers to transition to the new formulation with minimal disruption, thereby enhancing market competitiveness.
- Market Reaction: Although Lantheus's stock fell by 4.91% to $72.56 during regular trading, it showed a slight recovery in after-hours trading, indicating potential market confidence in the new product, which may influence future stock performance.
See More
Lantheus Holdings' PYLARIFY TruVu Injection Receives FDA Approval
- Stock Price Surge: Shares of Lantheus Holdings, Inc. (LNTH) rose 5% in after-hours trading on Friday, reflecting positive market sentiment towards the company's new product and indicating investor confidence in its future growth potential.
- FDA Approval: The company announced that its PYLARIFY TruVu injection has received approval from the U.S. Food and Drug Administration (FDA), marking a significant milestone for the product's application in imaging for prostate cancer patients, which is expected to enhance the company's competitiveness in the medical imaging market.
- Market Launch Timeline: The injection is expected to be commercially available in the fourth quarter of 2026, suggesting that the company will realize new revenue streams in the coming years, further driving its financial performance and market share growth.
- Strategic Implications: This approval not only strengthens Lantheus's product portfolio in the prostate cancer treatment space but may also attract more investor attention, enhancing the company's overall image and market position within the biopharmaceutical industry.
See More
Lantheus Launches New PSMA PET Imaging Agent PYLARIFY TruVu
- FDA Approval: Lantheus's PYLARIFY TruVu (piflufolastat F 18) has received FDA approval, marking a significant innovation in prostate cancer diagnostics, with a planned launch in Q4 2026 to meet clinical demand for high-quality diagnostic tools.
- Enhanced Manufacturing Efficiency: The new formulation is designed to improve product stability and manufacturing efficiency, expected to increase batch production capacity, allowing high-energy cyclotron manufacturing sites to reach broader markets and enhance patient accessibility.
- Addressing Clinical Needs: The launch of PYLARIFY TruVu will address the urgent need for greater patient accessibility identified by clinicians, significantly improving imaging accuracy and treatment decisions for prostate cancer patients.
- Significant Market Potential: Since May 2021, over 760,000 prostate cancer patients have undergone scans with PYLARIFY, and with the rising incidence of prostate cancer, the introduction of PYLARIFY TruVu will further solidify Lantheus's leadership position in the market.
See More
Lantheus Holdings Under Investigation for Securities Violations
- Revenue Decline: Lantheus Holdings reported an 8% year-over-year decline in Pylarify revenue in August 2025, contrasting sharply with the company's previous optimistic outlook, which has diminished market confidence in its growth potential.
- Guidance Cut: The company also lowered its full-year guidance while facing widespread contract renegotiations and account losses, exacerbating investor concerns regarding its financial health and future performance.
- Legal Action: Lantheus and certain executives are facing a securities class action lawsuit for failing to disclose material information, which violates federal securities laws, and this ongoing litigation could have long-term implications for the company's reputation and stock price.
- Investigation Launched: Kahn Swick & Foti has initiated an investigation into whether Lantheus' officers and directors breached their fiduciary duties to shareholders, and if findings indicate wrongdoing, it could lead to further legal consequences.
See More
Lantheus Holdings Exceeds 2025 Financial Expectations
- Strong Financial Performance: Lantheus Holdings reported nearly $407 million in revenue for Q4 2025, a 4% increase year-over-year, and despite a slight drop in net income to $111 million, it surpassed the analyst consensus estimate of $1.17 per share, indicating robust market performance.
- Strategic Focus Shift: The company announced a strategic pivot towards innovative radiodiagnostics, prioritizing investments in PET radiodiagnostics while seeking value-maximizing alternatives for its radiotherapeutic assets, reflecting a keen insight into future market demands.
- Sales Dynamics: Although sales of its cancer imaging agent Pylarify fell nearly 10% year-over-year to over $240 million in Q4, the precision diagnostics product category surged 22%, generating over $143 million in revenue, showcasing the company's potential in emerging markets.
- Optimistic 2026 Outlook: Lantheus anticipates revenue between $1.4 billion and $1.45 billion for 2026, with adjusted per-share net profit expected to be between $5 and $5.25, both exceeding current analyst estimates, indicating strong confidence and growth potential for the company.
See More
U.S. Stock Futures Lower, Investors Eye Individual Stocks
- Market Dynamics: U.S. stock futures opened lower this morning on Monday, reflecting a cautious investor sentiment that may influence trading strategies for the day.
- Investor Focus: Despite the overall market decline, certain individual stocks may still attract investor attention, indicating a trend of market differentiation that could lead to capital flowing into specific sectors or companies.
- Expected Volatility: Market participants anticipate greater volatility in the stock market as economic data releases and corporate earnings reports approach, which could impact investor decision-making.
- Data Source: This market analysis is provided by Benzinga, highlighting the importance of real-time tracking and analysis of market dynamics to assist investors in making more informed investment choices.
See More
Lantheus Receives FDA Approval for New Imaging Agent
- FDA Approval: Lantheus Holdings Inc. announced that its new F 18 prostate-specific membrane antigen imaging agent, PYLARIFY TruVu, has received approval from the U.S. Food and Drug Administration (FDA), marking a significant advancement in prostate cancer imaging.
- Defined Indication: PYLARIFY TruVu is indicated for positron emission tomography (PET) imaging in prostate cancer patients, particularly for those with suspected metastasis, which is expected to provide more accurate diagnostic tools for patients.
- Market Launch Plan: The product is expected to be commercially available in the fourth quarter of 2026 and will be introduced on a rolling geographic basis, allowing customers to transition to the new formulation with minimal disruption, thereby enhancing market competitiveness.
- Market Reaction: Although Lantheus's stock fell by 4.91% to $72.56 during regular trading, it showed a slight recovery in after-hours trading, indicating potential market confidence in the new product, which may influence future stock performance.
See More
Lantheus Holdings' PYLARIFY TruVu Injection Receives FDA Approval
- Stock Price Surge: Shares of Lantheus Holdings, Inc. (LNTH) rose 5% in after-hours trading on Friday, reflecting positive market sentiment towards the company's new product and indicating investor confidence in its future growth potential.
- FDA Approval: The company announced that its PYLARIFY TruVu injection has received approval from the U.S. Food and Drug Administration (FDA), marking a significant milestone for the product's application in imaging for prostate cancer patients, which is expected to enhance the company's competitiveness in the medical imaging market.
- Market Launch Timeline: The injection is expected to be commercially available in the fourth quarter of 2026, suggesting that the company will realize new revenue streams in the coming years, further driving its financial performance and market share growth.
- Strategic Implications: This approval not only strengthens Lantheus's product portfolio in the prostate cancer treatment space but may also attract more investor attention, enhancing the company's overall image and market position within the biopharmaceutical industry.
See More
Lantheus Launches New PSMA PET Imaging Agent PYLARIFY TruVu
- FDA Approval: Lantheus's PYLARIFY TruVu (piflufolastat F 18) has received FDA approval, marking a significant innovation in prostate cancer diagnostics, with a planned launch in Q4 2026 to meet clinical demand for high-quality diagnostic tools.
- Enhanced Manufacturing Efficiency: The new formulation is designed to improve product stability and manufacturing efficiency, expected to increase batch production capacity, allowing high-energy cyclotron manufacturing sites to reach broader markets and enhance patient accessibility.
- Addressing Clinical Needs: The launch of PYLARIFY TruVu will address the urgent need for greater patient accessibility identified by clinicians, significantly improving imaging accuracy and treatment decisions for prostate cancer patients.
- Significant Market Potential: Since May 2021, over 760,000 prostate cancer patients have undergone scans with PYLARIFY, and with the rising incidence of prostate cancer, the introduction of PYLARIFY TruVu will further solidify Lantheus's leadership position in the market.
See More
Lantheus Holdings Under Investigation for Securities Violations
- Revenue Decline: Lantheus Holdings reported an 8% year-over-year decline in Pylarify revenue in August 2025, contrasting sharply with the company's previous optimistic outlook, which has diminished market confidence in its growth potential.
- Guidance Cut: The company also lowered its full-year guidance while facing widespread contract renegotiations and account losses, exacerbating investor concerns regarding its financial health and future performance.
- Legal Action: Lantheus and certain executives are facing a securities class action lawsuit for failing to disclose material information, which violates federal securities laws, and this ongoing litigation could have long-term implications for the company's reputation and stock price.
- Investigation Launched: Kahn Swick & Foti has initiated an investigation into whether Lantheus' officers and directors breached their fiduciary duties to shareholders, and if findings indicate wrongdoing, it could lead to further legal consequences.
See More
